📣From lead to pre-candidate nomination in 18 months. Explore the STORM Therapeutics case study

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Event

17 April, 2026

Booth #2947, San Diego, CA, US

AACR 2026

Let’s meet at Booth #2947

AACR 2026

April 17–22, 2026 | San Diego, CA, USA

The AACR Annual Meeting 2026 takes place April 17 to 22 in San Diego, California. The meeting brings together researchers, clinicians, and patient advocates to discuss current work in cancer biology, detection, and therapeutic research. Program themes include precision medicine, multiomics, spatial transcriptomics, liquid biopsy approaches, tumor microenvironments, and immunotherapy.

Meet the Sygnature Team at AACR 2026

We will be attending AACR Annual Meeting 2026 throughout the week, taking part in scientific sessions and presenting a poster. AACR brings together teams working across early biology, chemistry, and translational research, making it a useful setting to discuss how design‑to‑biology, high‑throughput chemistry, and related workflows are being applied in active oncology programs. We will also be sharing how these approaches connect with our in vivo oncology and ADC work, where early biological and pharmacology data help teams make clearer decisions earlier in discovery.

If you would like to arrange a meeting with Allan Jordan, Tobias Bunday, Jason Dupuis or Lorraine Mooney, we are happy to schedule a time during the conference.

Book a Meeting

Allan Jordan – Vice President, Oncology Drug Discovery

Tobias Bunday – Discovery Services Consultant, in vivo Pharmacology

Jason Dupuis – Director, Business Development

Lorraine Mooney – Associate Director, Translational Oncology

Poster Presentations

Direct to Discovery: Extending Direct-to-Biology paradigms to accelerate oncology drug discovery.
Presenter: Allan Jordan
Date and time: April 21st, 2pm

Register to access the poster

Additional Resources

  • STORM Therapeutics: From Lead to Pre‑Candidate Nomination in 18 Months
    This case study outlines how our teams worked alongside STORM Therapeutics to advance a complex DHX9 inhibitor program through a connected chemistry‑biology approach. A fully integrated discovery plan, rapid iteration, and diverse hit‑finding strategies supported the program’s progression from lead to pre‑candidate nomination in 18 months, ahead of typical industry timelines.

Can’t attend AACR?
Connect with our team directly

Related Solutions

We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.

Direct-to-Biology

Embedding Direct‑to‑Biology methodologies into customer programs enables rapid, systematic expansion of SAR. This approach shortens the path to lead optimization and accelerates the delivery of candidate‑quality compounds.

Learn more
in vivo Pharmacology

in vivo Pharmacology

Validated in vivo models deliver clinically relevant data across therapeutic areas, accelerating confident decisions and reducing risk in drug development.

Learn more
Lead Optimization

Lead Optimisation

Transforming early leads into clinical-quality candidates through integrated expertise, rapid decision-making, and optimized strategies for safety, potency, and exposure.

Learn more
Antibody Drug Conjugates

Antibody Drug Conjugates

Discover more about our wide range capabilities to support ADC projects.

Learn more